Evaluation of human fetal bone implants in SCID mice as a model of prostate cancer bone metastasis

Oncology Reports

Volumn 15, Issue 3, 2006, Pages 519-524

  Singh, Arun S ^a,b   MacPherson, Gordon R ^a   Price, Douglas K ^a   Schimel, Daniel ^a   Figg, William Douglas ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

Bone; Cancer; Imaging; Luminescence; Metastasis; PC3; Prostate

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT; GREEN FLUORESCENT PROTEIN; IMIDAZOLE DERIVATIVE; LUCIFERASE; ZOLEDRONIC ACID;

ANIMAL; ARTICLE; BONE TRANSPLANTATION; BONE TUMOR; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECT; DRUG SCREENING; EVALUATION; FETUS; GENETIC TRANSFECTION; GENETICS; HUMAN; INSTRUMENTATION; LUMINESCENCE; MALE; METABOLISM; METASTASIS; METHODOLOGY; MOUSE; MOUSE MUTANT; PATHOLOGY; PLASMID; PROSTATE TUMOR; TUMOR CELL LINE;

ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE NEOPLASMS; BONE TRANSPLANTATION; CELL LINE, TUMOR; CELL PROLIFERATION; DIPHOSPHONATES; DOSE-RESPONSE RELATIONSHIP, DRUG; FETUS; GREEN FLUORESCENT PROTEINS; HUMANS; IMIDAZOLES; LUCIFERASES; LUMINESCENT MEASUREMENTS; MALE; MICE; MICE, SCID; PLASMIDS; PROSTATIC NEOPLASMS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33645747584     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.15.3.519     Document Type: Article

References (19)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ and Thun MJ: Cancer statistics. CA Cancer J Clin 55: 10-30, 2005.
2. Petrylak DP, Tangen CM, Hussain MH, Lara PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D and Crawford ED: Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351: 1513-1520, 2004. (Pubitemid 39315318)
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Theodore C, James ND, Turesson I, Rosenthal MA and Eisenberger MA: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351: 1502-1512, 2004. (Pubitemid 39315317)
4. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA and Chen B: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 94: 1458-1468, 2002.
5. Mundy GR: Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer 2: 584-593, 2002.
6. Charhon SA, Chapuy MC, Delvin EE, Valentin-Opran A, Edouard CM and Meunier PJ: Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma special reference to osteomalacia. Cancer 51: 918-924, 1983. (Pubitemid 13143171)
7. Galasko CS: Mechanisms of lytic and blastic metastatic disease of bone. Clin Orthop 169: 20-27, 1982.
8. Koutsilieris M: Osteoblastic metastasis in advanced prostate cancer. Anticancer Res 13: 443-449, 1993.
9. Urwin GH, Percival RC, Harris S, Beneton MN, Williams JL and Kanis JA: Generalised increase in bone resorption in carcinoma of the prostate. Br J Urol 57: 721-723, 1985. (Pubitemid 16211558)
10. Yi B, Williams PJ, Niewolna M, Wang Y and Yoneda T: Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 62: 917-923, 2002. (Pubitemid 34126973)
11. Corey E, Brown LG, Quinn JE, Poot M, Roudier MP, Higano CS and Vessella RL: Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 9: 295-306, 2003. (Pubitemid 36109746)
12. Lee YP, Schwarz EM, Davies M, Jo M, Gates J, Zhang X, Wu J and Lieberman JR: Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res 62: 5564-5570, 2002.
13. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350: 1655-1664, 2004.
14. Nemeth JA, Harb JF, Barroso U Jr, He Z, Grignon DJ and Cher ML: Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone. Cancer Res 59: 1987-1993, 1999. (Pubitemid 29186176)
15. Kozlowski JM, Fidler IJ, Campbell D, Xu ZL, Kaighn ME and Hart IR: Metastatic behavior of human tumor cell lines grown in the nude mouse. Cancer Res 44: 3522-3529, 1984. (Pubitemid 14098607)
16. Jenkins DE, Yu SF, Hornig YS, Purchio T and Contag PR: In vivomonitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer. Clin Exp Metastasis 20: 745-756, 2003. (Pubitemid 38019276)
17. Wang M and Stearns ME: Isolation and characterization of PC-3 human prostatic tumor sublines which preferentially metastasize to select organs in S.C.I.D. mice. Differentiation 48: 115-125, 1991.
18. Tsingotjidou AS, Zotalis G, Jackson KR, Sawyers C, Puzas JE, Hicks DG, Reiter R and Lieberman JR: Development of an animal model for prostate cancer cell metastasis to adult human bone. Anticancer Res 21: 971-978, 2001. (Pubitemid 32494195)
19. Haq M, Goltzman D, Tremblay G and Brodt P: Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res 52: 4613-4619, 1992.